You are here

    • You are here:
    • Home > "New laboratories join the CRG"

"New laboratories join the CRG"


Mon, 23/08/2010 - 16:42

"New laboratories join the CRG"

CRG continues to grow and to add new research groups. Recently three new laboratories have joined the institute. These new groups led by junior group leaders will join the existing research programmes.
Pedro Carvalho and his Organelle Biogenesis and Homeostasis Laboratory have joined the Cell and Developmental Biology Programme. His work focuses on mechanisms underlying Endoplasmatic Reticulum homeostasis. They try to understand how this organelle is able to generate and fold proteins or which are the mechanisms involved in lipid droplet formation. All these processes are studied using a combination of biochemical, genetic and imaging approaches. Pedro Carvalho obtained his PhD in Biomedical Sciences at the University of Porto, Portugal and he was at the Harvard Medical School in Boston, in the States, as a postdoctoral researcher before coming to the CRG.
Gian Gaetano Tartaglia heads the Gene Function and Evolution Laboratory within the Bioinformatics and Genomics Programme. Tartaglia’s group is focused on the understanding of regulation of gene expression and on the prediction of the mechanisms of protein folding. Studying protein-protein and protein-gene interactions they aim to find the conditions under which specific cellular pathways become aberrant and give rise to pathologies. Dr. Tartaglia was a postdoctoral researcher at the Dept. of Genetics and Chemistry at the University of Cambridge, in the UK. He obtained his PhD in Biochemistry at the University of Zurich, Switzerland.
Finally, Stephan Ossowski joins the Gene and Disease Programme with his Genomic and Epigenomic Variation in Disease laboratory. This young researcher uses next generation sequencing data in order to detect genomic, genic and epigenomic variation related to disease or intolerance to specific treatments. The group seeks to develop new analysis tools for related sequencing applications and it is clearly linked to new personalized medicine. Stephan Ossowski has recently obtained his PhD in the Max Planck Institute and the University of Tübingen, Germany. He was also at the Massachusetts Institute of Technology (MIT) in Boston, USA, for a short postdoctoral stay.